Home | Business News | Browse by Publication | P | PR Newswire

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Receives Not Approvable Letter for RISPERDAL(R) in the Treatment of Psychosis of Alzheimer's Disease.

Publication: PR Newswire
Publication Date: 26-MAY-05
Format: Online
Delivery: Immediate Online Access

Article Excerpt
RARITAN, N.J., May 26 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced it has received a not approvable letter from the U.S. Food and Drug Administration (FDA) regarding a Supplemental New Drug Application (sNDA) for RISPERDAL(R) (risperidone) in the treatment of psychosis of Alzheimer's disease.

Recognizing...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from PR Newswire
Steel Partners II, L.P. Wins ISS Support., May 26, 2005
TXU Corp. Announces Intent to Redeem Existing Preference Stock, Expect..., May 26, 2005
Immunomedics Announces Conference Call and Webcast., May 26, 2005
MRU Holdings, Inc. and Student Loan Solutions, LLC. (SLS) Sign Contrac..., May 26, 2005
Rush to Market in Nanosensors, But Most Aren't 'Nano'., May 26, 2005

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.